BeiGene Analysis
What is BeiGene?
BeiGene company profile.
Employees
10,600
Valuation
31.17B
Revenue Growth Rate
74%
Investment Focus
BeiGene primarily focuses on two therapeutic areas: Hematology and Solid Tumors. They are committed to developing innovative therapies for these specific types of cancer, addressing significant unmet medical needs in these fields.
Awards Recognition
BeiGene has received several awards and recognitions in the biotech field, including: 1. **Manufacturer of the Year** by the National Association of Specialty Pharmacy (NASP) in October 2024, recognizing its innovation and leadership in the specialty pharmacy sector. 2. **2023 PM360 Silver Pharma Choice Award** for its BTK Inhibitors AR Review entry in the Sales Aid category. 3. **Scrip Award** for contributions to improving healthcare across the pharmaceutical sector in December 2019. 4. **100 Best Ideas Award** by the Spanish business magazine Actualidad Económica for BeiGene Spain in May 2024.
Key Innovations
- Tislelizumab (Tevimbra) - A PD-1 inhibitor used for treating various cancers, including esophageal squamous cell carcinoma (ESCC) and gastric cancer. It has gained regulatory approvals in multiple regions, including the USA and Israel.
- Zanubrutinib (Brukinsa) - A Bruton's tyrosine kinase (BTK) inhibitor that is being evaluated for various hematological malignancies. It is designed to improve treatment outcomes for patients with blood cancers.
- Sonrotoclax - A BCL2 inhibitor that is part of their hematology development programs.
- Ociperlimab - A TIGIT monoclonal antibody that is also in their pipeline for cancer treatment.
- BGB-45035 - An IRAK4 inhibitor that targets specific pathways in cancer cells. BeiGene is recognized for its extensive pipeline, which includes over 60 pre-clinical programs and approximately 50 assets in clinical and commercial stages, focusing on making innovative cancer therapies more accessible globally.
Regulatory Approvals
- TEVIMBRA (tislelizumab) - Approved by the U.S. FDA for the treatment of advanced or metastatic esophageal squamous cell carcinoma after prior chemotherapy. It also received a positive opinion from the European Medicines Agency (EMA) for use in combination with chemotherapy for extensive-stage small cell lung cancer.
- BRUKINSA (zanubrutinib)
Partnerships
- ImmunityBio - A collaboration and supply agreement was signed to work together on research initiatives. - [Source](https://www.thepharmaletter.com/immunitybio-and-beigene-ink-research-collaboration)
- MAIA Biotechnology - A clinical supply agreement to evaluate the drug THIO in combination with tislelizumab in three Phase 2 pivotal trials. - [Source](https://www.stocktitan.net/news/MAIA/maia-biotechnology-announces-clinical-supply-agreement-with-bei-gene-md9qf0cqh7vt.html)
- InnoRNA - A strategic research collaboration to jointly discover novel mRNA therapies. - [Source](https://ir.beigene.com/news/beigene-announces-strategic-research-collaboration-with-innorna-to-jointly-discover-novel-mrna-therapies/1eed7555-e652-45b6-9345-19e423838d29/)
- Amgen - A strategic collaboration to advance 20 medicines from Amgen's oncology pipeline in China and globally. - [Source](https://www.amgen.com/newsroom/press-releases/2019/10/amgen-enters-into-strategic-collaboration-with-beigene-to-expand-oncology-presence-in-china)
- Nona Biosciences - An expanded collaboration for antibody discovery, utilizing Nona's proprietary technology. - [Source](https://nonabio.com/nona-biosciences-expands-antibody-discovery-collaboration-with-beigene/)
